Inovio Pharmaceuticals (NASDAQ:INO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a sell rating to a hold rating in a report released on Saturday.

Several other brokerages also recently commented on INO. Jefferies Financial Group raised Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and upped their price objective for the company from $1.80 to $3.00 in a research report on Thursday. Weiss Ratings downgraded Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Piper Sandler reissued an “overweight” rating and set a $4.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Thursday. Finally, Zacks Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $3.17.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ:INO opened at $1.15 on Friday. Inovio Pharmaceuticals has a 1 year low of $0.56 and a 1 year high of $2.98. The business has a 50 day simple moving average of $1.03 and a two-hundred day simple moving average of $1.30. The firm has a market capitalization of $118.91 million, a PE ratio of -1.26 and a beta of 1.52.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. Equities research analysts expect that Inovio Pharmaceuticals will post -0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Focus Partners Wealth bought a new stake in Inovio Pharmaceuticals during the 3rd quarter valued at $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 5,894 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Inovio Pharmaceuticals by 752.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 18,160 shares during the period. Raymond James Financial Inc. increased its stake in shares of Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 16,309 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Inovio Pharmaceuticals during the third quarter valued at $41,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.